Related Experiment Video

Updated: Aug 12, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

Prenatal drug exposure: effects on neonatal and infant growth and development

I J Chasnoff, K A Burns, W J Burns

    Neurobehavioral Toxicology and Teratology
    |July 1, 1986
    PubMed

    There is no question that the number of women using and abusing drugs other than opiates far exceeds the number who are addicted to narcotics. Data on four groups of drug-addicted pregnant women and their newborns are presented and compared to a drug-free control group. Group I women (N = 51) conceived while on heroin and were converted to low-dose methadone maintenance; Group II women were addicted to multiple licit or illicit nonnarcotic drugs (N = 22); Group III women abused a combination of pentazocine and tripelennamine (T's and blues) during pregnancy (N = 13); and Group IV women (N = 9) abused phencyclidine (PCP) throughout pregnancy. Group V women (N = 27) were selected from the clinic population of Prentice Women's Hospital and Maternity Center and had no history or evidence of substance use or abuse. Opiate-exposed newborns in Groups I and III were significantly smaller than control infants for all growth parameters, though by nine months of age they had caught up in weight and length to control infants. Head circumference remained significantly smaller than controls through two years of age. All four groups of drug-exposed infants exhibited abnormal neurobehavior in the newborn period, but mental and psychomotor development as evaluated with the Bayley Scales of Infant Development was comparable to control infants' development through two years of age.

    More Related Videos

    Construction of Vapor Chambers Used to Expose Mice to Alcohol During the Equivalent of all Three Trimesters of Human Development15:27

    Construction of Vapor Chambers Used to Expose Mice to Alcohol During the Equivalent of all Three Trimesters of Human Development

    Published on: July 13, 2014

    Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes05:13

    Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

    Published on: February 28, 2025

    Related Concept Videos

    Factors Affecting Drug Response: Overview01:21

    Factors Affecting Drug Response: Overview

    When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
    Teratogenicity01:07

    Teratogenicity

    The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
    Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

    Pharmacokinetics in Pediatric Patients: Drug Distribution

    Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
    Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

    Pharmacokinetics in Pediatric Patients: Drug Excretion

    In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
    Drug Toxicity: Risk factors01:24

    Drug Toxicity: Risk factors

    Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
    Drug Toxicity: Dose-Dependent Reactions01:24

    Drug Toxicity: Dose-Dependent Reactions

    Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...